Twenty-five year follow-up of childhood Wilms tumor: A report from the Childhood Cancer Survivor Study

Amanda M. Termuhlen, Jean M. Tersak, Qi Liu, Yutaka Yasui, Marilyn Stovall, Rita Weathers, Melvin Deutsch, Charles A. Sklar, Kevin C. Oeffinger, Gregory Armstrong, Leslie L. Robison, Daniel M. Green

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Background: Treatment cures over 90% of children with Wilms tumor (WT) who subsequently risk late morbidity and mortality. This study describes the 25-year outcomes of 5-year WT survivors in the Childhood Cancer Survivor Study (CCSS). Procedure: The CCSS, a multi-institutional retrospective cohort study, assessed WT survivors (N=1,256), diagnosed 1970-1986, for chronic health conditions, health status, health care utilization, socioeconomic status, subsequent malignant neoplasms (SMNs), and mortality compared to the US population and a sibling cohort (N=4,023). Results: The cumulative incidence of all and severe chronic health conditions was 65.4% and 24.2% at 25 years. Hazard ratios (HR) were 2.0, 95% confidence interval (CI) 1.8-2.3 for grades 1-4 and 4.7, 95%CI 3.6-6.1 for grades 3 and 4, compared to sibling group. WT survivors reported more adverse general health status than the sibling group (prevalence ratio [PR] 1.7; 95%CI 1.2-2.4), but mental health status, socioeconomic outcome, and health care utilization were similar. The cumulative incidence of SMN was 3.0% (95%CI 1.9-4.0%) and of mortality was 6.1% (95%CI 4.7-7.4%). Radiation exposure increased the likelihood of congestive heart failure (CHF) (no doxorubicin-HR 6.6; 95%CI 1.6-28.3; doxorubicin ≤250mg/m 2-HR 13.0; 95%CI 1.9-89.7; doxorubicin >250mg/m 2-HR 18.3; 95%CI 3.8-88.2), SMN (standardized incidence ratio [SIR] 9.0; 95%CI 3.9-17.7 with and 4.9; 95%CI 1.8-10.6 without doxorubicin) and death. Conclusion: Long-term survivors of WT treated from 1970 to 1986 are at increased risk of treatment related morbidity and mortality 25 years from diagnosis.

Original languageEnglish (US)
Pages (from-to)1210-1216
Number of pages7
JournalPediatric Blood and Cancer
Volume57
Issue number7
DOIs
StatePublished - Dec 15 2011

Fingerprint

Wilms Tumor
Survivors
Confidence Intervals
Neoplasms
Doxorubicin
Patient Acceptance of Health Care
Health Status
Siblings
Mortality
Incidence
Morbidity
Health
Social Class
Mental Health
Cohort Studies
Heart Failure
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Termuhlen, A. M., Tersak, J. M., Liu, Q., Yasui, Y., Stovall, M., Weathers, R., ... Green, D. M. (2011). Twenty-five year follow-up of childhood Wilms tumor: A report from the Childhood Cancer Survivor Study. Pediatric Blood and Cancer, 57(7), 1210-1216. https://doi.org/10.1002/pbc.23090

Twenty-five year follow-up of childhood Wilms tumor : A report from the Childhood Cancer Survivor Study. / Termuhlen, Amanda M.; Tersak, Jean M.; Liu, Qi; Yasui, Yutaka; Stovall, Marilyn; Weathers, Rita; Deutsch, Melvin; Sklar, Charles A.; Oeffinger, Kevin C.; Armstrong, Gregory; Robison, Leslie L.; Green, Daniel M.

In: Pediatric Blood and Cancer, Vol. 57, No. 7, 15.12.2011, p. 1210-1216.

Research output: Contribution to journalArticle

Termuhlen, AM, Tersak, JM, Liu, Q, Yasui, Y, Stovall, M, Weathers, R, Deutsch, M, Sklar, CA, Oeffinger, KC, Armstrong, G, Robison, LL & Green, DM 2011, 'Twenty-five year follow-up of childhood Wilms tumor: A report from the Childhood Cancer Survivor Study', Pediatric Blood and Cancer, vol. 57, no. 7, pp. 1210-1216. https://doi.org/10.1002/pbc.23090
Termuhlen, Amanda M. ; Tersak, Jean M. ; Liu, Qi ; Yasui, Yutaka ; Stovall, Marilyn ; Weathers, Rita ; Deutsch, Melvin ; Sklar, Charles A. ; Oeffinger, Kevin C. ; Armstrong, Gregory ; Robison, Leslie L. ; Green, Daniel M. / Twenty-five year follow-up of childhood Wilms tumor : A report from the Childhood Cancer Survivor Study. In: Pediatric Blood and Cancer. 2011 ; Vol. 57, No. 7. pp. 1210-1216.
@article{c3a58a489c7f41fea9fdf883f28f2bb2,
title = "Twenty-five year follow-up of childhood Wilms tumor: A report from the Childhood Cancer Survivor Study",
abstract = "Background: Treatment cures over 90{\%} of children with Wilms tumor (WT) who subsequently risk late morbidity and mortality. This study describes the 25-year outcomes of 5-year WT survivors in the Childhood Cancer Survivor Study (CCSS). Procedure: The CCSS, a multi-institutional retrospective cohort study, assessed WT survivors (N=1,256), diagnosed 1970-1986, for chronic health conditions, health status, health care utilization, socioeconomic status, subsequent malignant neoplasms (SMNs), and mortality compared to the US population and a sibling cohort (N=4,023). Results: The cumulative incidence of all and severe chronic health conditions was 65.4{\%} and 24.2{\%} at 25 years. Hazard ratios (HR) were 2.0, 95{\%} confidence interval (CI) 1.8-2.3 for grades 1-4 and 4.7, 95{\%}CI 3.6-6.1 for grades 3 and 4, compared to sibling group. WT survivors reported more adverse general health status than the sibling group (prevalence ratio [PR] 1.7; 95{\%}CI 1.2-2.4), but mental health status, socioeconomic outcome, and health care utilization were similar. The cumulative incidence of SMN was 3.0{\%} (95{\%}CI 1.9-4.0{\%}) and of mortality was 6.1{\%} (95{\%}CI 4.7-7.4{\%}). Radiation exposure increased the likelihood of congestive heart failure (CHF) (no doxorubicin-HR 6.6; 95{\%}CI 1.6-28.3; doxorubicin ≤250mg/m 2-HR 13.0; 95{\%}CI 1.9-89.7; doxorubicin >250mg/m 2-HR 18.3; 95{\%}CI 3.8-88.2), SMN (standardized incidence ratio [SIR] 9.0; 95{\%}CI 3.9-17.7 with and 4.9; 95{\%}CI 1.8-10.6 without doxorubicin) and death. Conclusion: Long-term survivors of WT treated from 1970 to 1986 are at increased risk of treatment related morbidity and mortality 25 years from diagnosis.",
author = "Termuhlen, {Amanda M.} and Tersak, {Jean M.} and Qi Liu and Yutaka Yasui and Marilyn Stovall and Rita Weathers and Melvin Deutsch and Sklar, {Charles A.} and Oeffinger, {Kevin C.} and Gregory Armstrong and Robison, {Leslie L.} and Green, {Daniel M.}",
year = "2011",
month = "12",
day = "15",
doi = "10.1002/pbc.23090",
language = "English (US)",
volume = "57",
pages = "1210--1216",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Twenty-five year follow-up of childhood Wilms tumor

T2 - A report from the Childhood Cancer Survivor Study

AU - Termuhlen, Amanda M.

AU - Tersak, Jean M.

AU - Liu, Qi

AU - Yasui, Yutaka

AU - Stovall, Marilyn

AU - Weathers, Rita

AU - Deutsch, Melvin

AU - Sklar, Charles A.

AU - Oeffinger, Kevin C.

AU - Armstrong, Gregory

AU - Robison, Leslie L.

AU - Green, Daniel M.

PY - 2011/12/15

Y1 - 2011/12/15

N2 - Background: Treatment cures over 90% of children with Wilms tumor (WT) who subsequently risk late morbidity and mortality. This study describes the 25-year outcomes of 5-year WT survivors in the Childhood Cancer Survivor Study (CCSS). Procedure: The CCSS, a multi-institutional retrospective cohort study, assessed WT survivors (N=1,256), diagnosed 1970-1986, for chronic health conditions, health status, health care utilization, socioeconomic status, subsequent malignant neoplasms (SMNs), and mortality compared to the US population and a sibling cohort (N=4,023). Results: The cumulative incidence of all and severe chronic health conditions was 65.4% and 24.2% at 25 years. Hazard ratios (HR) were 2.0, 95% confidence interval (CI) 1.8-2.3 for grades 1-4 and 4.7, 95%CI 3.6-6.1 for grades 3 and 4, compared to sibling group. WT survivors reported more adverse general health status than the sibling group (prevalence ratio [PR] 1.7; 95%CI 1.2-2.4), but mental health status, socioeconomic outcome, and health care utilization were similar. The cumulative incidence of SMN was 3.0% (95%CI 1.9-4.0%) and of mortality was 6.1% (95%CI 4.7-7.4%). Radiation exposure increased the likelihood of congestive heart failure (CHF) (no doxorubicin-HR 6.6; 95%CI 1.6-28.3; doxorubicin ≤250mg/m 2-HR 13.0; 95%CI 1.9-89.7; doxorubicin >250mg/m 2-HR 18.3; 95%CI 3.8-88.2), SMN (standardized incidence ratio [SIR] 9.0; 95%CI 3.9-17.7 with and 4.9; 95%CI 1.8-10.6 without doxorubicin) and death. Conclusion: Long-term survivors of WT treated from 1970 to 1986 are at increased risk of treatment related morbidity and mortality 25 years from diagnosis.

AB - Background: Treatment cures over 90% of children with Wilms tumor (WT) who subsequently risk late morbidity and mortality. This study describes the 25-year outcomes of 5-year WT survivors in the Childhood Cancer Survivor Study (CCSS). Procedure: The CCSS, a multi-institutional retrospective cohort study, assessed WT survivors (N=1,256), diagnosed 1970-1986, for chronic health conditions, health status, health care utilization, socioeconomic status, subsequent malignant neoplasms (SMNs), and mortality compared to the US population and a sibling cohort (N=4,023). Results: The cumulative incidence of all and severe chronic health conditions was 65.4% and 24.2% at 25 years. Hazard ratios (HR) were 2.0, 95% confidence interval (CI) 1.8-2.3 for grades 1-4 and 4.7, 95%CI 3.6-6.1 for grades 3 and 4, compared to sibling group. WT survivors reported more adverse general health status than the sibling group (prevalence ratio [PR] 1.7; 95%CI 1.2-2.4), but mental health status, socioeconomic outcome, and health care utilization were similar. The cumulative incidence of SMN was 3.0% (95%CI 1.9-4.0%) and of mortality was 6.1% (95%CI 4.7-7.4%). Radiation exposure increased the likelihood of congestive heart failure (CHF) (no doxorubicin-HR 6.6; 95%CI 1.6-28.3; doxorubicin ≤250mg/m 2-HR 13.0; 95%CI 1.9-89.7; doxorubicin >250mg/m 2-HR 18.3; 95%CI 3.8-88.2), SMN (standardized incidence ratio [SIR] 9.0; 95%CI 3.9-17.7 with and 4.9; 95%CI 1.8-10.6 without doxorubicin) and death. Conclusion: Long-term survivors of WT treated from 1970 to 1986 are at increased risk of treatment related morbidity and mortality 25 years from diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=80053903886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053903886&partnerID=8YFLogxK

U2 - 10.1002/pbc.23090

DO - 10.1002/pbc.23090

M3 - Article

C2 - 21384541

AN - SCOPUS:80053903886

VL - 57

SP - 1210

EP - 1216

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 7

ER -